Literature DB >> 21638191

Percutaneous endoscopic sigmoid colostomy for irrigation in the management of bowel dysfunction of adults with central neurologic disease.

A Ramwell1, M Rice-Oxley, A Bond, J N L Simson.   

Abstract

BACKGROUND: Bowel dysfunction results in a major lifestyle disruption for many patients with severe central neurologic disease. Percutaneous endoscopic sigmoid colostomy for irrigation (PESCI) allows antegrade irrigation of the distal large bowel for the management of both incontinence and constipation. This study prospectively assessed the safety and efficacy of PESCI.
METHODS: A PESCI tube was placed endoscopically in the sigmoid colon of 25 patients to allow antegrade irrigation.
RESULTS: Control of constipation and fecal incontinence was improved for 21 (84%) of the 25 patients. These patients were followed up for 6-83 months (mean, 43 months), with long-term success for 19 (90%) of the patients. No PESCI had to be removed for technical reasons or for PESCI complications. Late removal of the PESCI was necessary for 2 of the 21 patients. A modified St. Marks Fecal Incontinence Score to assess bowel function before and after PESCI showed a highly significant improvement (P < 0.0001). There were no procedure-related deaths. Complications included minor sepsis at the initial PESCI tube site in four patients and bumper migration in two patients, but there were no complications related to the button device.
CONCLUSION: This study showed that PESCI is a simple, safe, and effective technique for distal antegrade irrigation in the management bowel dysfunction for selected patients with central neurologic disease. A successful PESCI is very likely to continue functioning satisfactorily for a long time without technical problems or local complications.

Entities:  

Mesh:

Year:  2011        PMID: 21638191     DOI: 10.1007/s00464-011-1701-6

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  28 in total

1.  Endoscopically placed caecostomy buttons: a trial ACE procedure.

Authors:  D Biyani; E Barrow; P Hodson; A J M Watson; I Maclennan
Journal:  Colorectal Dis       Date:  2007-05       Impact factor: 3.788

2.  Preliminary report: the antegrade continence enema.

Authors:  P S Malone; P G Ransley; E M Kiely
Journal:  Lancet       Date:  1990-11-17       Impact factor: 79.321

3.  The antegrade continence enema procedure why, when and how?

Authors:  P S Malone; J I Curry; A Osborne
Journal:  World J Urol       Date:  1998       Impact factor: 4.226

4.  Continent catheterizable conduits: which stoma, which conduit and which reservoir?

Authors:  H F McAndrew; P S J Malone
Journal:  BJU Int       Date:  2002-01       Impact factor: 5.588

5.  Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis.

Authors:  P H Wiesel; C Norton; A J Roy; J B Storrie; J Bowers; M A Kamm
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

Review 6.  Pathophysiology and management of bowel dysfunction in multiple sclerosis.

Authors:  P H Wiesel; C Norton; S Glickman; M A Kamm
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-04       Impact factor: 2.566

7.  Left-colon antegrade continence enema (LACE) procedure for fecal incontinence.

Authors:  Bernard M Churchill; Daniel A De Ugarte; James B Atkinson
Journal:  J Pediatr Surg       Date:  2003-12       Impact factor: 2.545

8.  Constipation and the preached trio: diet, fluid intake, exercise.

Authors:  Merilyn Annells; Tina Koch
Journal:  Int J Nurs Stud       Date:  2003-11       Impact factor: 5.837

Review 9.  Left Antegrade Continent Enema (LACE): review of the literature.

Authors:  C K Sinha; C Butler; M Haddad
Journal:  Eur J Pediatr Surg       Date:  2008-08-14       Impact factor: 2.191

10.  Management of bowel dysfunction in children with spinal cord disease or injury by means of the enema continence catheter.

Authors:  G S Liptak; G M Revell
Journal:  J Pediatr       Date:  1992-02       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.